Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Cipla Limited
WARNING LETTER
•Cipla Limited•September 27, 2019

Cipla Limited – FDA Warning Letter, Sep 27, 2019

Record Details

The FDA issued a Warning Letter to Cipla Limited, Mumbai, India, following an inspection of their Verna, Goa drug manufacturing facility from September 16-27, 2019. The inspection revealed significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals, rendering their drug products adulterated under 21 U.S.C. 351(a)(2)(B).

Key violations include: 1. **Inadequate Equipment Cleaning (21 CFR 211.67(a)):** Investigators found residues of different products in exhaust ducts and confirmed cross-contamination of active ingredients in subsequent batches (e.g., [b][4] active ingredient in [b][4] tablets). The firm's response was deemed inadequate, lacking a clear root cause and comprehensive assessment of contamination scope. Required actions include a comprehensive, independent retrospective assessment of cleaning effectiveness, a CAPA plan for cleaning processes, and an updated cleaning validation program.

2. **Failure to Thoroughly Investigate Discrepancies (21 CFR 211.192):** The firm failed to adequately investigate numerous HEPA filter failures in late 2018, which compromised aseptic conditions. Approximately 80 batches for the U.S. market were potentially impacted. The investigation lacked sufficient data to assess the impact on marketed batches and address environmental monitoring excursions. Required actions include a comprehensive, independent

Company
Cipla Limited
Inspection date
September 27, 2019
Product type
Drugs
Office
Center for Drug Evaluation and Research
Person
  • Francis Godwin (Director)
View Company Profile

ID · 6321f828-da26-4571-b32c-638dd2cf14df

Violation Codes10
21 CFR 21021 CFR 211FD&C Act 501(a)(2)(B)21 CFR 211.67(a)21 CFR 211.19221 CFR 211.113(b)FD&C Act 801(a)(3)21 U.S.C. 381(a)(3)21 U.S.C. 356C(b)21 U.S.C. 351(a)(2)(B)

Full citation text and observation details available on the Dashboard.

Other documents for Cipla Limited
  • 483 - 2026-08-25August 25, 2026
  • WARNING_LETTER - 2023-02-17February 17, 2023
  • 483 - 2023-02-17February 17, 2023
  • 483 - 2022-07-01July 1, 2022
  • 483 - 2018-04-13April 13, 2018

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Cipla Limited
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.